Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report

Medicine (Baltimore). 2018 Nov;97(48):e13410. doi: 10.1097/MD.0000000000013410.

Abstract

Rationale: Triple-negative breast cancer (TNBC) is associated with unfavorable prognosis due to lack of targeted agents. Bevacizumab, an anti-angiogenic monoclonal antibody against vascular endothelial growth factor A, has shown clinical effects in patients with TNBC.

Patient concerns: We reported a 49-year-old woman presenting with a giant breast tumor.

Diagnoses: Stage IV TNBC with chest wall metastasis.

Interventions: The patient underwent long-term use of bevacizumab combined with chemotherapy.

Outcomes: The patient was on follow-up for 46 months, a remarkable improvement of the chest wall cutaneous lesion was observed.

Lessons: Bevacizumab may provide benefits for TNBC patients with chest wall metastasis.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab / administration & dosage*
  • Carcinoma, Ductal / drug therapy*
  • Carcinoma, Ductal / pathology
  • Carcinoma, Ductal / secondary*
  • Cisplatin / administration & dosage
  • Female
  • Humans
  • Middle Aged
  • Thoracic Neoplasms / drug therapy*
  • Thoracic Neoplasms / pathology
  • Thoracic Neoplasms / secondary*
  • Thoracic Wall / drug effects
  • Thoracic Wall / pathology
  • Treatment Outcome
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / pathology
  • Vascular Endothelial Growth Factor A / drug effects

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Cisplatin